» Articles » PMID: 35740453

Molecular Pathophysiological Mechanisms in Huntington's Disease

Overview
Journal Biomedicines
Date 2022 Jun 24
PMID 35740453
Authors
Affiliations
Soon will be listed here.
Abstract

Huntington's disease is an inherited neurodegenerative disease described 150 years ago by George Huntington. The genetic defect was identified in 1993 to be an expanded CAG repeat on exon 1 of the huntingtin gene located on chromosome 4. In the following almost 30 years, a considerable amount of research, using mainly animal models or in vitro experiments, has tried to unravel the complex molecular cascades through which the transcription of the mutant protein leads to neuronal loss, especially in the medium spiny neurons of the striatum, and identified excitotoxicity, transcriptional dysregulation, mitochondrial dysfunction, oxidative stress, impaired proteostasis, altered axonal trafficking and reduced availability of trophic factors to be crucial contributors. This review discusses the pathogenic cascades described in the literature through which mutant huntingtin leads to neuronal demise. However, due to the ubiquitous presence of huntingtin, astrocytes are also dysfunctional, and neuroinflammation may additionally contribute to Huntington's disease pathology. The quest for therapies to delay the onset and reduce the rate of Huntington's disease progression is ongoing, but is based on findings from basic research.

Citing Articles

Human striatal progenitor cells that contain inducible safeguards and overexpress BDNF rescue Huntington's disease phenotypes.

Simmons D, Selvaraj S, Chen T, Cao G, Camelo T, McHugh T Mol Ther Methods Clin Dev. 2025; 33(1):101415.

PMID: 39995448 PMC: 11848452. DOI: 10.1016/j.omtm.2025.101415.


Serum neurofilament light chain but not serum glial fibrillary acidic protein is a marker of early Huntington's disease.

Heim B, Mandler E, Peball M, Carbone F, Schwarzova K, Demjaha R J Neurol. 2025; 272(2):174.

PMID: 39891767 PMC: 11787204. DOI: 10.1007/s00415-025-12901-y.


Neuroinflammation and neurodegeneration in Huntington's disease: genetic hallmarks, role of metals and organophosphates.

Kunwar O, Singh S Neurogenetics. 2025; 26(1):21.

PMID: 39820855 DOI: 10.1007/s10048-025-00801-2.


Advances in Stem Cell Therapy for Huntington's Disease: A Comprehensive Literature Review.

Shah S, Mansour H, Lucke-Wold B Cells. 2025; 14(1.

PMID: 39791743 PMC: 11719515. DOI: 10.3390/cells14010042.


Pathophysiological role of high mobility group box-1 signaling in neurodegenerative diseases.

Kumar V, Kumar P Inflammopharmacology. 2024; 33(2):703-727.

PMID: 39546221 DOI: 10.1007/s10787-024-01595-9.


References
1.
Rebec G . Corticostriatal network dysfunction in Huntington's disease: Deficits in neural processing, glutamate transport, and ascorbate release. CNS Neurosci Ther. 2018; 24(4):281-291. PMC: 6489880. DOI: 10.1111/cns.12828. View

2.
Harding R, Tong Y . Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities. Acta Pharmacol Sin. 2018; 39(5):754-769. PMC: 5943907. DOI: 10.1038/aps.2018.11. View

3.
Hwang J, Zukin R . REST, a master transcriptional regulator in neurodegenerative disease. Curr Opin Neurobiol. 2018; 48:193-200. PMC: 5892838. DOI: 10.1016/j.conb.2017.12.008. View

4.
Lee J, Westrate L, Wu H, Page C, Voeltz G . Multiple dynamin family members collaborate to drive mitochondrial division. Nature. 2016; 540(7631):139-143. PMC: 5656044. DOI: 10.1038/nature20555. View

5.
Shimojo M . Huntingtin regulates RE1-silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) nuclear trafficking indirectly through a complex with REST/NRSF-interacting LIM domain protein (RILP) and dynactin p150 Glued. J Biol Chem. 2008; 283(50):34880-6. PMC: 2596380. DOI: 10.1074/jbc.M804183200. View